AU2022384375A1 - Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer - Google Patents
Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer Download PDFInfo
- Publication number
- AU2022384375A1 AU2022384375A1 AU2022384375A AU2022384375A AU2022384375A1 AU 2022384375 A1 AU2022384375 A1 AU 2022384375A1 AU 2022384375 A AU2022384375 A AU 2022384375A AU 2022384375 A AU2022384375 A AU 2022384375A AU 2022384375 A1 AU2022384375 A1 AU 2022384375A1
- Authority
- AU
- Australia
- Prior art keywords
- psma
- ligand compound
- pharmaceutically acceptable
- integer
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111329108.1 | 2021-11-10 | ||
| CN202111329108 | 2021-11-10 | ||
| PCT/CN2022/130833 WO2023083209A1 (zh) | 2021-11-10 | 2022-11-09 | 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022384375A1 true AU2022384375A1 (en) | 2024-05-09 |
Family
ID=86335105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022384375A Pending AU2022384375A1 (en) | 2021-11-10 | 2022-11-09 | Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260069725A1 (https=) |
| EP (1) | EP4431503A1 (https=) |
| JP (1) | JP2024544870A (https=) |
| KR (1) | KR20240105380A (https=) |
| CN (1) | CN118176188A (https=) |
| AU (1) | AU2022384375A1 (https=) |
| CA (1) | CA3237743A1 (https=) |
| TW (1) | TW202321204A (https=) |
| WO (1) | WO2023083209A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118852044A (zh) | 2021-09-03 | 2024-10-29 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| CN117069670B (zh) * | 2023-07-31 | 2026-04-10 | 复旦大学附属华山医院 | 靶向psma的二聚体化合物及其衍生物和应用 |
| CN119954773A (zh) * | 2023-10-31 | 2025-05-09 | 苏州威智创科生物有限公司 | Psma化合物、包含其的药物组合物及其用途 |
| WO2025167998A1 (zh) * | 2024-02-06 | 2025-08-14 | 北京昌平实验室 | 膦酸酯骨架的psma靶向偶联物 |
| CN118221764A (zh) * | 2024-03-05 | 2024-06-21 | 苏州大学 | 一种双靶向分子探针及其制备方法与应用 |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629201B2 (en) * | 2017-05-24 | 2023-04-18 | ITM Isotope Technologies Munich SE | PSMA-binding agents and uses thereof |
| US20200339625A1 (en) * | 2017-10-22 | 2020-10-29 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| CN114401947B (zh) * | 2019-06-21 | 2024-11-29 | 省卫生服务机构 | 靶向前列腺特异性膜抗原的放射性标记化合物 |
-
2022
- 2022-11-09 JP JP2024527096A patent/JP2024544870A/ja active Pending
- 2022-11-09 CA CA3237743A patent/CA3237743A1/en active Pending
- 2022-11-09 TW TW111142867A patent/TW202321204A/zh unknown
- 2022-11-09 US US18/708,905 patent/US20260069725A1/en active Pending
- 2022-11-09 AU AU2022384375A patent/AU2022384375A1/en active Pending
- 2022-11-09 CN CN202280074508.9A patent/CN118176188A/zh active Pending
- 2022-11-09 EP EP22892003.9A patent/EP4431503A1/en active Pending
- 2022-11-09 KR KR1020247014634A patent/KR20240105380A/ko active Pending
- 2022-11-09 WO PCT/CN2022/130833 patent/WO2023083209A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024544870A (ja) | 2024-12-05 |
| CN118176188A (zh) | 2024-06-11 |
| KR20240105380A (ko) | 2024-07-05 |
| EP4431503A1 (en) | 2024-09-18 |
| CA3237743A1 (en) | 2023-05-19 |
| TW202321204A (zh) | 2023-06-01 |
| US20260069725A1 (en) | 2026-03-12 |
| WO2023083209A1 (zh) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022384375A1 (en) | Ligand compound targeting psma antigen, and chelate and use thereof in diagnosis and treatment of prostate cancer | |
| KR101639599B1 (ko) | 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물 | |
| CN102911256B (zh) | 一种放射性标记的多肽配合物及其制备方法和应用 | |
| EP0831938B1 (en) | Radiolabeled peptide compositions for site-specific targeting | |
| CN111905112A (zh) | 靶向pd-l1的多肽复合物及其应用 | |
| JP7541532B2 (ja) | 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物 | |
| CN118955478B (zh) | 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物 | |
| EP4474379A1 (en) | Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative | |
| JP2023179429A (ja) | キレート化ａａｚｔａコンジュゲートおよびその錯体 | |
| JP2024532521A (ja) | ペプチド－尿素誘導体、それを含む医薬組成物、及びそれらの使用 | |
| TW202543589A (zh) | 丹磺醯胺修飾的psma靶向化合物及其製備方法和應用 | |
| CN107308466B (zh) | 具有肿瘤血管靶向性的多肽、分子探针及其制备方法和应用 | |
| CN120943901A (zh) | 经修饰的caix靶向环肽、核素标记物及其在肿瘤诊疗方面的应用 | |
| PL239934B1 (pl) | Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty | |
| CN118666964A (zh) | 一种靶向肿瘤pd-l1的pet示踪剂、其标记前体、制备方法和应用 | |
| EP2537834B1 (en) | Polyazamacrocyclic compound, and a production method and a biomedical use therefor | |
| Serdons et al. | Development of 99mTc‐thioflavin‐T derivatives for detection of systemic amyloidosis | |
| CA2151099A1 (en) | Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide | |
| KR101658201B1 (ko) | 전립선암의 진단 및 치료를 위한 가스트린유리펩티드수용체 작용서열 기반의 신규한 봄베신 유도체 화합물 | |
| CN114685608B (zh) | 含有三硫醚键的环肽化合物或其衍生物、其合成方法和应用 | |
| JP2001507345A (ja) | 多糖ペプチド誘導体 | |
| WO2024051794A1 (zh) | 放射性核素偶联药物及其药物组合物和应用 | |
| CN121270660A (zh) | D肽靶向肿瘤pd-l1的放射性诊疗药物及其标记前体、制备方法和应用 | |
| WO2025153101A1 (zh) | 一种含氮化合物及其制备方法与用途 | |
| CN121949443A (zh) | 一种靶向at1r的化合物、pet示踪剂及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CHENGDU STARRAY THERAPEUTICS CO., LTD. Free format text: FORMER APPLICANT(S): SUZHOU RUIHE MEDICINE TECHNOLOGY CO., LTD |